Revenue
2020
2021
2022
Candel Therapeutics, Inc. (CADL)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $125,000 | $125,000 | $125,000 |
| Research & development | $30.5M | $19.3M | $24.5M | $20.8M | $15.2M | $8.8M |
| Operating expenses | $48.3M | $33.4M | $38.4M | $34.8M | $25.9M | $13.9M |
| Operating income | −$48.3M | −$33.4M | −$38.4M | −$34.7M | −$25.7M | −$13.8M |
| EBITDAderived | — | — | — | −$33.9M | −$25.5M | −$13.7M |
| Net income | −$38.2M | −$55.2M | −$37.9M | −$18.8M | −$36.1M | −$17.7M |
| Basic EPSper diluted share | -$0.72 | -$1.74 | -$1.31 | -$0.65 | -$1.91 | -$1.52 |
| Diluted EPSper diluted share | -$0.72 | -$1.74 | -$1.31 | -$0.65 | -$1.91 | -$1.52 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 23, 2026Form 4 | Manning Paul BDirector | BuyCommon Stock · indirect | 550.5K | $5.45 | $3.00M | 2.76M |
| Jul 28, 2025Form 4 · 10b5-1 | Nichols William GarrettChief Medical Officer | SellCommon Stock | 937 | $6.98 | $6.5K | 52.5K |
| Jun 30, 2025Form 4 · 10b5-1 | Nichols William GarrettChief Medical Officer | SellCommon Stock | 781 | $5.04 | $3.9K | 52.5K |
| Mar 19, 2025Form 4 · 10b5-1 | Tak Paul PeterChief Executive Officer | SellCommon Stock | 400 | $9.00 | $3.6K | 225.7K |
| Mar 18, 2025Form 4 · 10b5-1 | Nichols William GarrettChief Medical Officer | SellCommon Stock | 45.3K | $8.76 | $397.0K | 52.5K |